Drug burden index of people ageing with intellectual disability and cognitive complaints attending a specialist memory service.
intellectual disability
learning disability
psychiatric disorders
treatment and services
Journal
Journal of intellectual disability research : JIDR
ISSN: 1365-2788
Titre abrégé: J Intellect Disabil Res
Pays: England
ID NLM: 9206090
Informations de publication
Date de publication:
26 Aug 2024
26 Aug 2024
Historique:
revised:
05
07
2024
received:
18
05
2023
accepted:
29
07
2024
medline:
27
8
2024
pubmed:
27
8
2024
entrez:
27
8
2024
Statut:
aheadofprint
Résumé
Medications with sedative or anticholinergic properties should be prescribed with caution in those with cognitive complaints. This is particularly relevant in people ageing with an intellectual disability (ID). Higher drug burden index (DBI) scores are associated with increased frailty and falls and reduced quality of life in older people and increased risk of adverse effects (daytime somnolence, constipation) in those with ID. While previous studies have shown that the ID population has higher rates of drug burden and a higher propensity to be prescribed an antipsychotic than the general population, the degree of burden has not been assessed specifically in those with ID and cognitive complaints. We assessed drug burden in a cohort of sequential referrals to a national memory service for people with ID. All patients were referred for assessment of cognitive complaints (self-reported or caregiver-reported problems with memory or cognition). DBI was calculated individually for each participant, and the impact of aetiology of ID, level of ID, age, psychiatric/neurological comorbidities and diagnostic outcome on DBI scores was assessed. The study population was 58.6% female with a median age of 55 years and aetiology of ID was Down syndrome (DS) in 71.3%. Consensus diagnosis was Alzheimer's dementia in 40.2%, mild cognitive impairment in 29.9% and cognitively unimpaired from baseline in 25.3%. Medication use was high with 95.4% taking medications, with a median number of medications of 4 (interquartile range 4) and a rate of polypharmacy (≥5 medications) of 51.7%. Overall, 65.5% were exposed to sedative or anticholinergic medications with 39.1% exposed to a clinically significant DBI score >1. Those with psychiatric comorbidities, non-DS aetiology or epilepsy were significantly more likely to have a DBI score >1. People with ID and incipient cognitive complaints have a high level of drug burden, which concerningly exceeds that of the general population.
Sections du résumé
BACKGROUND
BACKGROUND
Medications with sedative or anticholinergic properties should be prescribed with caution in those with cognitive complaints. This is particularly relevant in people ageing with an intellectual disability (ID). Higher drug burden index (DBI) scores are associated with increased frailty and falls and reduced quality of life in older people and increased risk of adverse effects (daytime somnolence, constipation) in those with ID. While previous studies have shown that the ID population has higher rates of drug burden and a higher propensity to be prescribed an antipsychotic than the general population, the degree of burden has not been assessed specifically in those with ID and cognitive complaints.
METHODS
METHODS
We assessed drug burden in a cohort of sequential referrals to a national memory service for people with ID. All patients were referred for assessment of cognitive complaints (self-reported or caregiver-reported problems with memory or cognition). DBI was calculated individually for each participant, and the impact of aetiology of ID, level of ID, age, psychiatric/neurological comorbidities and diagnostic outcome on DBI scores was assessed.
RESULTS
RESULTS
The study population was 58.6% female with a median age of 55 years and aetiology of ID was Down syndrome (DS) in 71.3%. Consensus diagnosis was Alzheimer's dementia in 40.2%, mild cognitive impairment in 29.9% and cognitively unimpaired from baseline in 25.3%. Medication use was high with 95.4% taking medications, with a median number of medications of 4 (interquartile range 4) and a rate of polypharmacy (≥5 medications) of 51.7%. Overall, 65.5% were exposed to sedative or anticholinergic medications with 39.1% exposed to a clinically significant DBI score >1. Those with psychiatric comorbidities, non-DS aetiology or epilepsy were significantly more likely to have a DBI score >1.
CONCLUSIONS
CONCLUSIONS
People with ID and incipient cognitive complaints have a high level of drug burden, which concerningly exceeds that of the general population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons and MENCAP.
Références
Ahmed Z., Fraser W., Kerr M. P., Kiernan C., Emerson E., Robertson J. et al. (2000) Reducing antipsychotic medication in people with a learning disability. The British Journal of Psychiatry 176, 42–46.
Axmon A., Kristensson J., Ahlström G. & Midlöv P. (2017) Use of antipsychotics, benzodiazepine derivatives, and dementia medication among older people with intellectual disability and/or autism spectrum disorder and dementia. Research in Developmental Disabilities 62, 50–57.
Ball S., Holland T., Huppert F. A., Treppner P. & Dodd K. (2006) CAMDEX‐DS: The Cambridge Examination for Mental Disorders of Older People with Down's Syndrome and Others with Intellectual Disabilities, vol. 1. Cambridge University Press.
Belton A., O'Dwyer M., Peklar J., McCallion P., McCarron M. & Henman M. C. (2018) Medication use and health screening in an ageing adult population with Down syndrome in Ireland: a descriptive study. Journal of Policy and Practice in Intellectual Disabilities 15, 145–154.
Bhaumik S. & Branford D. (2005) Frith prescribing guidelines for adults with learning disability. CRC Press.
Bottiggi K. A., Salazar J. C., Yu L., Caban‐Holt A. M., Mendiondo M. S., Schmitt F. A. et al. (2006) Long‐term cognitive impact of anticholinergic medications in older adults. The American Journal of Geriatric Psychiatry 14, 980–984.
Branford D. & Shankar R. (2022) Antidepressant prescribing for adult people with an intellectual disability living in England. The British Journal of Psychiatry 221, 488–493.
Byrne C. J., Walsh C., Cahir C., Ryan C., Williams D. J. & Bennett K. (2018) Anticholinergic and sedative drug burden in community‐dwelling older people: a national database study. BMJ Open 8, e022500.
Byrne C. J., Walsh C., Cahir C. & Bennett K. (2019) Impact of drug burden index on adverse health outcomes in Irish community‐dwelling older people: a cohort study. BMC Geriatrics 19, 121.
Cooper S. A., Allan L., Greenlaw N., McSkimming P., Jasilek A., Henderson A. et al. (2020) Rates, causes, place and predictors of mortality in adults with intellectual disabilities with and without Down syndrome: cohort study with record linkage. BMJ Open 10, e036465.
Coppus A. M. W. (2013) People with intellectual disability: what do we know about adulthood and life expectancy? Developmental Disabilities Research Reviews 18, 6–16.
Deb S., Hare M., Prior L. & Bhaumik S. (2007) Dementia screening questionnaire for individuals with intellectual disabilities. The British Journal of Psychiatry 190, 440–444.
Department of Health (2019) Appropriate prescribing of psychotropic medication for non‐cognitive symptoms in people with dementia (NCEC National Clinical Guideline No. 21). Available at: https://www.gov.ie/en/collection/c9fa9a‐national‐clinical‐guidelines
Devshi R., Shaw S., Elliott‐King J., Hogervorst E., Hiremath A., Velayudhan L. et al. (2015) Prevalence of behavioural and psychological symptoms of dementia in individuals with learning disabilities. Diagnostics 5, 564–576.
Dodd K., Watchman K., Janicki M. P., Coppus A., Gaertner C., Fortea J. et al. (2018) Consensus statement of the international summit on intellectual disability and dementia related to post‐diagnostic support. Aging and Mental Health 22, 1406–1415.
Dyer A. H., Murphy C., Segurado R., Lawlor B., Kennelly S. P. & NILVAD Study Group (2020) Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer's disease? The Journals of Gerontology: Series A 75, 987–994.
de Gage S. B., Bégaud B., Bazin F., Verdoux H., Dartigues J. F., Pérès K. et al. (2012) Benzodiazepine use and risk of dementia: prospective population based study. British Medical Journal 345, e6231.
Gedye A. (1998) Neuroleptic‐induced dementia documented in four adults with mental retardation. Mental Retardation 36, 182–186.
Gnjidic D., Bell J. S., Hilmer S. N., Lönnroos E., Sulkava R. & Hartikainen S. (2012) Drug Burden Index associated with function in community‐dwelling older people in Finland: a cross‐sectional study. Annals of Medicine 44, 458–467.
Gnjidic D., Le Couteur D. G., Hilmer S. N., Cumming R. G., Blyth F. M., Naganathan V. et al. (2014) Sedative load and functional outcomes in community‐dwelling older Australian men: the CHAMP study. Fundamental and Clinical Pharmacology 28, 10–19.
Hampel H., Mesulam M. M., Cuello A. C., Farlow M. R., Giacobini E., Grossberg G. T. et al. (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain 141, 1917–1933.
Henderson A., Mcskimming P., Kinnear D., McCowan C., McIntosh A., Allan L. et al. (2020) Changes over a decade in psychotropic prescribing for people with intellectual disabilities: prospective cohort study. BMJ Open 10, e036862.
Hilmer S. N., Mager D. E., Simonsick E. M., Cao Y., Ling S. M., Windham B. G. et al. (2007) A drug burden index to define the functional burden of medications in older people. Archives of Internal Medicine 167, 781–787.
Hilmer S. N., Mager D. E., Simonsick E. M., Ling S. M., Windham B. G., Harris T. B. et al. (2009) Drug burden index score and functional decline in older people. The American Journal of Medicine 122, 1142–1149.
Kouladjian L., Gnjidic D., Chen T. F., Mangoni A. A. & Hilmer S. N. (2014) Drug Burden Index in older adults: theoretical and practical issues. Clinical Interventions in Aging 9, 1503.
McCarron M., McCallion P., Reilly E., Dunne P., Carroll R. & Mulryan N. (2017) A prospective 20‐year longitudinal follow‐up of dementia in persons with Down syndrome. Journal of Intellectual Disability Research 61, 843–852.
McKhann G. M., Knopman D. S., Chertkow H., Hyman B. T., Jack C. R., Jr., Kawas C. H. et al. (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 7, 263–269.
McMahon M., Hatton C. & Bowring D. L. (2020) Polypharmacy and psychotropic polypharmacy in adults with intellectual disability: a cross‐sectional total population study. Journal of Intellectual Disability Research 64, 834–851.
Mintzer J. & Burns A. (2000) Anticholinergic side‐effects of drugs in elderly people. Journal of the Royal Society of Medicine 93, 457–462.
Monaghan R., O'Dwyer M., Luus R., Mulryan N., McCallion P., McCarron M. et al. (2021) The relationship between antiepileptic drug load and challenging behaviors in older adults with intellectual disability and epilepsy. Epilepsy and Behavior 122, 108191.
Nabhanizadeh A., Oppewal A., Boot F. H. & Maes‐Festen D. (2019) Effectiveness of medication reviews in identifying and reducing medication‐related problems among people with intellectual disabilities: a systematic review. Journal of Applied Research in Intellectual Disabilities 32, 750–761.
National Institute for Health and Care Excellence (NICE) (2018) Dementia: assessment, management and support for people living with dementia and their carers at Available at: www.nice.org.uk/guidance/ng97 PMID: 30011160.
Ng N., Sandberg M. & Ahlström G. (2015) Prevalence of older people with intellectual disability in Sweden: a spatial epidemiological analysis. Journal of Intellectual Disability Research 59, 1155–1167.
O'Connell J., Burke É., Mulryan N., O'Dwyer C., Donegan C., McCallion P. et al. (2018) Drug burden index to define the burden of medicines in older adults with intellectual disabilities: an observational cross‐sectional study. British Journal of Clinical Pharmacology 84, 553–567.
O'Dwyer M., Maidment I. D., Bennett K., Peklar J., Mulryan N., McCallion P. et al. (2016) Association of anticholinergic burden with adverse effects in older people with intellectual disabilities: an observational cross‐sectional study. The British Journal of Psychiatry 209, 504–510.
O'Dwyer M., Peklar J., Mulryan N., McCallion P., McCarron M. & Henman M. C. (2018) Prevalence and patterns of anti‐epileptic medication prescribing in the treatment of epilepsy in older adults with intellectual disabilities. Journal of Intellectual Disability Research 62, 245–261.
O'Dwyer M., Watkins L., McCallion P., McCarron M., Henman M. & Shankar R. (2021) Optimising medicines use in older adults with intellectual disability who have epilepsy: challenges and perspectives. Therapeutic Advances in Drug Safety 12, 20420986211025157.
O'Leary L., Hughes‐McCormack L., Dunn K. & Cooper S. A. (2018) Early death and causes of death of people with Down syndrome: a systematic review. Journal of Applied Research in Intellectual Disabilities 31, 687–708.
Peklar J., O'Halloran A. M., Maidment I. D., Henman M. C., Kenny R. A. & Kos M. (2015) Sedative load and frailty among community‐dwelling population aged ≥65 years. Journal of the American Medical Directors Association 16, 282–289.
Petersen R. C. (2004) Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 256, 183–194.
Richardson K., Fox C., Maidment I., Steel N., Loke Y. K., Arthur A. et al. (2018) Anticholinergic drugs and risk of dementia: case‐control study. British Medical Journal 361, k1315.
Royal College of Psychiatrists (2021) Position Statement PS05/21: stopping the over‐prescribing of people with intellectual disability, autism or both (STOMP) and supporting treatment and appropriate medication in paediatrics (STAMP).
Scheifes A., Walraven S., Stolker J. J., Nijman H. L., Egberts T. C. & Heerdink E. R. (2016) Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs. Research in Developmental Disabilities 49, 13–21.
Shankar R., Wilcock M., Deb S., Goodey R., Corson E., Pretorius C. et al. (2019) A structured programme to withdraw antipsychotics among adults with intellectual disabilities: the Cornwall experience. Journal of Applied Research in Intellectual Disabilities 32, 1389–1400.
Sheehan R. & Hassiotis A. (2017) Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review. The Lancet Psychiatry 4, 238–256.
Sheehan R., Horsfall L., Strydom A., Osborn D., Walters K. & Hassiotis A. (2017) Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population‐based cohort study. BMJ Open 7, e017406.
Strydom A., Chan T., King M., Hassiotis A. & Livingston G. (2013) Incidence of dementia in older adults with intellectual disabilities. Research in Developmental Disabilities 34, 1881–1885.
Sun J. J., Perera B., Henley W., Angus‐Leppan H., Sawhney I., Watkins L. et al. (2022) Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study. Journal of Neurology 269, 2750–2760.
Taylor‐Rowan M., Edwards S., Noel‐Storr A. H., McCleery J., Myint P. K., Soiza R. et al. (2021) Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database of Systematic Reviews 5. https://doi.org/10.1002/14651858.CD013540.pub2
Taylor‐Rowan M., Kraia O., Kolliopoulou C., Noel‐Storr A. H., Alharthi A. A., Cross A. J. et al. (2022) Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia. Cochrane Database of Systematic Reviews 8. https://doi.org/10.1002/14651858.CD015196.pub2
Ward L. M., Stanley B., Greenlaw N., Cooper S. A., Pacitti C., Henderson A. et al. (2021) Risk of anticholinergic burden in adults with intellectual disabilities: a Scottish retrospective cohort study of n = 17 220. Journal of Intellectual Disability Research 65, 813–830.
Ward L. M., Cooper S. A., Henderson A., Stanley B., Greenlaw N., Pacitti C. et al. (2022) A study on prescriptions contributing to the risk of high anticholinergic burden in adults with intellectual disabilities: retrospective record linkage study. Annals of General Psychiatry 21, 41.